Miracle Leaf® qualifying-conditions guide

Medical Marijuana for Glaucoma

Group of eye diseases that damage the optic nerve, usually associated with elevated intraocular pressure. Cannabis transiently lowers intraocular pressure, but the effect duration is too short to be clinically useful; the American Academy of Ophthalmology and the American Glaucoma Society do not recommend cannabis as glaucoma treatment.

Reviewed by Miracle Leaf® Editorial Team

Last reviewed 2026-05-15

Book Evaluation Call (833) LEGAL-MJ

NASEM evidence levelLimitedICD-10: H40.9

What is Glaucoma?

Glaucoma is a group of eye diseases that damage the optic nerve. The most common form, primary open-angle glaucoma, is typically associated with elevated intraocular pressure (IOP), though some patients develop optic-nerve damage at normal IOP. Untreated, glaucoma causes irreversible vision loss. Standard treatment lowers IOP via topical eye drops, laser procedures, or surgery.

Does cannabis help Glaucoma?

Smoked or oral cannabis is known to transiently lower intraocular pressure. The effect lasts approximately three to four hours, requiring near-continuous dosing to maintain therapeutic IOP reduction. A regimen the American Academy of Ophthalmology and American Glaucoma Society explicitly do not recommend, citing concerns about side effects, impairment, and the availability of more effective treatments.

Despite the lack of clinical-society endorsement, glaucoma remains a qualifying condition under many state medical cannabis programs. This represents a historical artifact of early state ballot initiatives rather than current clinical consensus. California's Proposition 215 (1996) and Arizona's Proposition 200 listed glaucoma prominently.

Important: patients with glaucoma should not substitute cannabis for prescribed IOP-lowering eye drops, laser procedures, or surgery. Untreated or under-treated glaucoma causes permanent, irreversible vision loss. Discuss cannabis use with your ophthalmologist before adjusting any prescribed glaucoma therapy.

Eligibility

State eligibility for Glaucoma

Whether this condition is listed varies by state program. A Miracle Leaf® physician determines eligibility during your evaluation.

State-by-state eligibility for Glaucoma: whether the condition qualifies under Florida, Georgia, and Texas medical cannabis programs.
State	Qualifies?	Program
Florida	Yes	Florida OMMU
Georgia	Not listed	Georgia DPH Low-THC Registry
Texas	Not listed	Texas Compassionate Use Program

Outside Florida, Georgia, or Texas?

Telehealth visits are available in 22 states. See telehealth states

Common questions

Frequently asked questions

Does cannabis lower intraocular pressure in glaucoma?

Yes, but only transiently. Inhaled or ingested cannabis lowers intraocular pressure for roughly three to four hours per dose. Sustained IOP control (the actual goal of glaucoma therapy) requires consistent 24-hour pressure reduction, which cannabis cannot provide without continuous around-the-clock dosing at levels associated with substantial systemic side effects.

What is the official position of ophthalmology specialty societies?

The American Academy of Ophthalmology and the American Glaucoma Society both recommend against the use of cannabis as glaucoma treatment. Their position is that the short duration of effect, systemic side effects, and the availability of effective topical, laser, and surgical options make cannabis unsuitable as primary therapy.

Is any cannabis-derived product FDA-approved for glaucoma?

No. No cannabis or cannabinoid product is FDA-approved for glaucoma. Standard glaucoma therapy uses topical prostaglandin analogs, beta-blockers, alpha-agonists, and carbonic anhydrase inhibitors, plus laser trabeculoplasty and surgical procedures (trabeculectomy, drainage implants, minimally invasive glaucoma surgery).

Why is glaucoma still a qualifying condition in many state medical-cannabis programs?

Glaucoma was enumerated in the earliest state programs (California 1996 and most subsequent statutes) based on the IOP-lowering observation. Most state legislatures have not removed glaucoma despite the AAO/AGS position. The result is a divergence between legal qualifying status (broad) and current clinical-evidence recommendation (against). Patients should discuss with both their ophthalmologist and their certifying practitioner.

Sources and citations

Ready to talk with a Miracle Leaf® physician?

Book Evaluation Call (833) LEGAL-MJ Shop Now

Reviewed by Miracle Leaf® Editorial Team. This page summarizes current peer-reviewed evidence and federal guidance and is updated when the source documents materially change.